Kornimate/medical-research-clean huggingface dataset:
head-cancelled virtual reality for ocular cranial nerve palsies

Conditions: Internuclear Ophthalmoplegia; Palsy, Abducens

Summary: this study is investigating whether eye exercises for abducens palsy and internuclear ophthalmoplegia increase ocular range of motion in the paretic direction when performed in virtual reality under head-cancelled compared to head-active conditions.

participants with abducens palsy or internuclear ophthalmoplegia, two common types of ocular cranial nerve palsies, will perform 3 different tasks in virtual reality under head-cancelled and head-active conditions. head active is the normal state, where gaze can be shifted by moving the head, the eyes, or a combination of the two. head-cancelled refers to the condition where the scene moves with the head, rendering head movement ineffective to shift gaze. in this condition, the eyes must move in order to shift gaze. the hypothesis is that this requirement for eye movement will result in larger eye movements, which could be therapeutic. the tasks performed under the two conditions will include horizontal transposition of coins, repetitive horizontal saccades, and game play. the primary analysis will be a within subject's comparison of eye movement amplitude in head-cancelled (experimental) versus head-active (control) conditions. additionally, as a control comparison for secondary analysis, a group with normal vision will also perform the tasks under both conditions.

Eligibility criteria:
ocnp group inclusion criteria: * presence of ocnp in one eye with 50% range-of-motion limitation or worse * able to provide informed consent and will be able to fluently read and understand spoken english ocnp group exclusion criteria: * presence of bilateral ocnp * range of motion better than 50% * visual acuity worse than 20/100 in either eye * greater than 4-line difference in visual acuity between the eyes, * structural anomalies or sensory sensitivities (e.g. visual motion sensitivity) that would prevent them from wearing or tolerating a vr headset participants will be excluded if they are unable to participate if inclusion criteria are not met. normal group inclusion criteria: * absence of ocnp or other neurological or neuro-ophthalmic diseases * no strabismus * have normal or near-normal vision with glasses or contact lenses. * be able to provide informed consent and will be able to fluently read and understand spoken english normal group exclusion criteria: * visual acuity worse than 20/100 in either eye * greater than 4-line difference in visual acuity between the eyes * structural anomalies or sensory sensitivities (e.g. visual motion sensitivity) that would prevent them from wearing or tolerating a vr headset * known inability to tolerate visual testing of at least 20 minutes continuously.
patient satisfaction after silicone metacarpophalangeal arthroplasty

Conditions: Rheumatoid Arthritis - Hand Joint

Summary: the primary objective of this study is to identify determinants of long-term patient satisfaction after hand reconstruction using silicone metacarpophalangeal arthroplasty (smpa). the investigators hypothesize that appearance of the hand, ulnar drift, range of motion, pain, hand function and intake of the newer antirheumatic drugs (i.e. biologicals) influence patient satisfaction.

this is an ambidirectional, monocenter research project consisting of a retrospective chart review and a prospective cohort project. participants fulfilling all of the following inclusion criteria are eligible for the project: * patients with rheumatoid arthritis (ra) / psoriasisarthritis / lupus erythomatodes who had a smpa between jan 2007 and one year before the project examination * informed consent as documented by signature the presence of any one of the following exclusion criteria will lead to exclusion of the participant: * major surgery at another joint at the hand (e.g. proximal interphalangeal (pip) joint arthroplasty, thumb trapeziectomy) less than 6 months ago * legal incompetence * german language barrier to complete the questionnaires

Eligibility criteria:
inclusion criteria: * patients with ra / psoriasisarthritis / lupus erythomatodes who had a smpa between jan 2007 and one year before the project examination * informed consent as documented by signature exclusion criteria: * major surgery at another joint at the hand (e.g. pip arthroplasty, thumb trapeziectomy) less than 6 months ago * legal incompetence * german language barrier to complete the questionnaires
evaluation of niti shape memory end-to-end compression anastomosis ring (car) for compression anastomosis in anterior resection

Conditions: Colorectal Cancer

Summary: the purpose of this study is to evaluate the safety and effectiveness of the niti car device in the creation of colorectal anastomosis


Eligibility criteria:
inclusion criteria: * patient age over 18 years * patient scheduled for colorectal cancer surgery * patient is able to comprehend and sign the informed consent form exclusion criteria: * patient has known allergy to nickel * patient with bowel obstruction, bowel strangulation, peritonitis, bowel perforation, local or systemic infection * patients who are participating in another trial * patient on regular steroid medication * patients who are undergoing a stoma * patients with contraindications to general anesthesia * patient with preexisting sphincter problems or evidence of extensive local disease in the pelvis * patients after radiation * patients who refuse consent
fotonasmooth erbium:yag laser for the treatment of urethral pain syndrome in women

Conditions: Pelvic Pain Syndrome

Summary: urethral pain syndrome (ups) is defined by the occurrence of persistent or recurrent episodic urethral pain in the absence of proven infection or other obvious pathology. the objective of this study is to determine the effect of an intraurethral and vaginal laser therapy for the treatment of ups. the hypothesis is that a significant reduction of urethral pressure pain can be achieved.

urethral pain syndrome (ups) is characterized by recurrent or persistent symptoms such as urethral or pelvic pain, daytime frequency and nocturia with unclear aetiology are diagnosed as ups. chronic infection by fastidious bacteria leading to chronic inflammation and pain may also cause ups. due to the unclear aetiology, the optimal treatment is challenging. it is therefore essential to find new and effective treatment options for patients suffering from ups. over the last few years, the use of lasers has become more popular to treat gynaecological and urogynecological conditions including stress urinary incontinence (sui), genitourinary syndrome of menopause (gsm), vaginal prolapse and other conditions. in several trials, vaginal laser therapy has been shown to have a very good effect on sui and gsm. very few publications are available on the use of intraurethral laser therapy for the treatment of sui and gsm with promising results. this is the first study to test the effect of intraurethral and vaginal laser therapy for the treatment of ups. the hypothesis is that symptoms can be relieved in patients with ups i.e. a reduction of urethral pressure pain upon palpation can be achieved.

Eligibility criteria:
inclusion criteria: * adult female, 18 years of age or older * urethral pressure pain upon palpation, vas score ≥ 2 * intermittent or chronic pain in the urethra and/or the small pelvis (independent of micturition) for at least 6 months * no significant improvement of ups from at least one previous conservative treatment (pessary, antibiotics, local oestrogens etc.) * signed informed consent exclusion criteria: * pregnancy * treatment with isotretinoin (acne, rosacea) within last 6 months * acute urinary tract infection or other acute infection of the bladder, vagina, vulva or urinary tract detected by routine urine analysis * positive urethral swab for ureaplasma, mycoplasma or chlamydia ≤ 6 weeks. exception: patients with chronic and persistent fastidious bacteria can be included six weeks after two unsuccessful treatments with antibiotics. antibiotics therapy must also include sexual partners. * pre-existing bladder or urethra pathology * interstitial cystitis * endometriosis * diagnosis of collagen disorders, e.g. benign joint hypermobility / elhers-danlos / marfans etc. * vesicovaginal fistula * unwillingness or inability to complete follow-up schedule * unwillingness or inability to give informed consent * unwillingness or inability to complete questionnaires

Keywords: urethra pain laser intraurethral erbium fotona
detection of valvular heart disease using artificial intelligence-based stethoscope

Conditions: Valvular Heart Disease

Summary: the aim of this study is to develop a deep learning-based application of heart sounds in the diagnosis of valvular heart disease, which can be used to screen patients with valvular heart disease and promote earlier clinical monitoring and intervention.


Eligibility criteria:
inclusion criteria: 1. age\>18 years 2. in the past 1 month, echocardiography was performed to diagnose valvular heart disease (positive group) and echocardiography to exclude valvular heart disease (negative group). 3. consent to study and be able to sign informed consent exclusion criteria: 1. after prosthetic valve replacement 2. congenital heart disease (except bilobal aortic valve) 3. hypertrophic cardiomyopathy（hcm） 4. pregnant, lactating women
organ donor tissue oxygen saturation as a predictor of number of organs to transplant per donor

Conditions: Brain Death

Summary: the objective of this study is to quantify the association between tissue oxygen saturation (sto2) during the donor management phase of the death by neurological criteria (dnc) organ donor and the number of organs transplanted per donor.

specifically the study aims to: 1. evaluate the association between sto2 level in the dnc organ donor and the number of organs transplanted per donor; 2. evaluate whether or not tissue perfusion in the dnc organ donor population correlates with currently measured macro-hemodynamic variables during the donor management phase. 3. assess if sto2 in the dnc organ donor is related to the number of organs with normal end-organ function, and with the number of organs predicted to be transplanted using the organ donor calculator. 4. assess if sto2 in the dnc organ donor is related with intravenous thyroid hormone treatment. investigators will conduct an observational study, including 60 dnc organ donors, in lifebanc's donor service area (dsa). investigators will monitor and record blindly the sto2 with near-infrared spectroscopy (nirs) in the dnc organ donor from the beginning of the opo (organ procurement organization) organ donor management period until cardiac arrest in the operating room at the time of recovery.

Eligibility criteria:
inclusion criteria: 1. dnc organ donor 2. age ≥ 15 years old 3. weight ≥ 45 kg exclusion criteria: 1. donor after circulatory determination of death 2. living donor

Keywords: tissue oxygen saturation management of the dnc organ donor
stress reduction: a pilot study with adolescents

Conditions: Physiological Stress; Psychological Stress

Summary: this study will evaluate the feasibility of providing an onsite mindfulness intervention, delivered as part of the school health curriculum, to help high school-attending adolescents cope with stress.

for this study, sophomores who are enrolled in health at jesuit high school, (n = 320 students) will be invited to participate in a research study, conducted during health class, comparing mindfulness to a wellness or waitlist control. the students will be randomized by classroom, to either wellness or mindfulness or waitlist, with approximately 3-4 classes per intervention or control. initially, six classes or sections of health will be randomized to one of the two active interventions, with the remaining classes/sections of health on the waitlist. both of the intervention groups will meet weekly, during one of the regularly scheduled health classes, and have daily assignments. the students in the waitlisted classrooms will receive an intervention at the start of the next term. at the end of the study, students will have access to the materials from the other group, if desired.

Eligibility criteria:
gender: •both: both female and male participants are being studied age for students: •minimum age 13 year, 0 months; •maximum:16 years, 0 months age for parents: n/a° inclusion criteria: adolescents who are enrolled in health class at jesuit high school, * who have access to an ipad, cell phone or computer, * are considered reliable and compliant with the study protocol including willing to abide by randomization process, willingness to commit to daily practice activities for the duration of the study. * students taking psychiatric medication including stimulants, anti-depressants or anxiolytics are eligible to participate provided they are stable on their current dose of medication, have been taking it for at least two weeks, and will remain on the same dose for the remainder of the study. any changes in medication will be noted. exclusion: * intellectual disability, as reported by parent or teacher; * current manic episode * psychotic episode * untreated post traumatic stress disorder, identified through parent or student report. exclusion criteria: -
the study of quadruple therapy intranasal insulin, zinc, gabapentin, ice cube stimulation for post covid-19 smell and taste dysfunctions

Conditions: Smell Dysfunction; Taste Disorders; Taste Disorder, Secondary, Sweet; Taste Disorder, Secondary, Bitter; Smell Disorder

Summary: post covid-19 smell and taste dysfunction are common globally and affect the quality of life and also have phycological impact and anxiety, also affect on economy as the patients not able to do cooking or buy prepared foods and not eaten, also not able to enter the cooking room and prepare foods for themselves, also the risk of loss of smell the fire accidents because anosmia, many forms of smell dysfunction like anosmia ,hyposmia, and dysosmia ,phantosmia , parosmia may occurred, the same taste disorders may has many forms like dysgeusia, phantom taste perception, hypogeusia with dysgeusia. until now no definite treatments for post covid-19 smell and taste disorders , this study is novel study as quadruple therapy intranasal insulin, zinc, gabapentin, ice cube stimulation may suspect having promising results

post covid-19 smell and taste dysfunction are common globally and affect the quality of life and also have phycological impact and anxiety, also effect on economy as the patients not able to do cooking or buy prepared foods and not eaten, also not able to enter the cooking room and prepare foods for themselves, also the risk of loss of smell the fire accidents because anosmia, many forms of smell dysfunction like anosmia , hyposmia, and dysosmia , phantosmia , parosmia may occurred, the same taste disorders may has many forms like dysgeusia, phantom taste perception, hypogeusia . until now no definite treatments for post covid-19 smell and taste disorders , this study is novel study as quadruple therapy intranasal insulin, zinc, gabapentin, ice cube stimulation may suspect having promising results. the application of intranasal insulin in healthy humans has been linked to improve memory function and increased olfactory thresholds also enhance the olfactory performance and regenerate the olfactory epithelium which the corner stone mechanism at affection of smell and taste disorders. zinc orally has many functions and improve taste and influence the activity of carbonic anhydrase in saliva which is important in breaking down foods in our mouth . the application of small ice cube in the mouth for one minute may improve seat taste and lower temperature by 5 degrees. gabapentin working by altering or blocking abnormal electrical discharges arising from the peripheral damaged smell or taste organ

Eligibility criteria:
inclusion criteria: * adult male or female recovered patients only postcovid-19 no other interventional treatment exclusion criteria: less than 18 years any nasal deviation or congenital anomalies any allergic sinusitis or nasal problems pregnant women's -
a study of jmt601 in participants with relapsed or refractory cd20-positive b-cell non-hodgkin lymphoma

Conditions: B-cell Non Hodgkin Lymphoma

Summary: this is a phase 1, open-label, multi-center study to evaluate the safety of jmt601 in the treatment of relapsed or refractory cd20-positive b-cell non-hodgkin lymphoma and to determine the recommended dose for phase 2 studies (rp2d). study consists of 2 parts. the first part is a dose-escalation part using a 3+3 design with up to 6 dose(0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, 12 mg/kg and 20 mg/kg) escalation cohorts at increasing levels. the second part is a dose-expansion part at r2pd dose to assess preliminary efficacy of jmt601.


Eligibility criteria:
key inclusion criteria: * participants diagnosed with cd20-positive b-cell non-hodgkin lymphoma confirmed by histopathology and/or cell biology who have previously received 2 or more lines of therapy * eastern cooperative oncology group (ecog) physical state score: 0-2 * participants must have at least one evaluable or measurable lesion according to lugano 2014 criteria. * expected survival of at least 3 months; * suitable organ and hematopoietic function: 1. the absolute count of neutrophil (anc) ≥1.0×109/l; 2. platelets ≥75×10\^9/l (if bone marrow invasion doesn't exist)/≥50.0×10\^9/l (if bone marrow invasion exists); 3. hemoglobin ≥90 g/l; 4. serum creatinine ≤1.5×uln or creatinine clearance ≥50 ml/min; 5. total bilirubin ≤1.5×uln, alanine aminotransferase ≤2.5×uln, aspartate aminotransferase ≤2.5×uln; subjects with liver lesion: tbil≤3×uln, alt≤5×uln, ast≤5×uln; 6. international standardized ratio and activated partial thromboplastin time ≤1.5 × uln; key exclusion criteria: * confirmed central nervous system (cns) lymphoma. * subjects who have received allogeneic hematopoietic stem cell transplantation (hsct) or other organ transplantation * those who have previously received targeted cd47 or signal regulatory protein α (sirrp α) therapy. * previous or current hemolytic anemia, evans syndrome, arteritis; * subjects with previous or current other malignant tumors; * previous or current history of active autoimmune diseases; * subjects who had undergone major surgery within 4 weeks prior to initial dosing or expected to have major surgery during the study period; * hiv infection, active syphilis, hepatitis b surface antigen (hbsag) positive and hbv-dna higher than the lower limit or 1000 copies /ml(500 iu/ml), hcv antibody positive and hcv-rna higher than the lower limit or 1000 copies /ml
clinical guidance for proper treatment of unexplained resistant hyperprolactinemia.

Conditions: Health Education

Summary: many women despite being well-treated in proper dose, with proper drug and for proper duration, may not respond to different forms of prolactin normalizing drugs. this will lead to extension of the treatment duration up to months or even years. doctors usually increase the dose of the drug with high possibility of side effects and even complications. some doctors change drug group to another without any significant improvement of hyperprolactinemia. hyperprolactinemia can indicate a deeper issue, about 10 percent of the population has hyperprolactinemia. life style, feeding habits and sexual behaviors are usually not included in the management protocols of hyperprolactinemia. aim of the study: this study will be aimed to: test the impact of clinical guidance to increase women's awareness of some contributing factors to help proper treatment of unexplained resistant hyperprolactinemia not responding to therapeutic da (cabergoline 1.5-2 mg/week). hypothesis of the study: h1- health education for women under drugs of hyperprolactinemia is effective to reduce the level of prolactin. h0- health education for women under drugs of hyperprolactinemia is not effective in reducing the level of prolactin

subjects and methods: all women diagnosed to have hyperprolactinemia as diagnosed by one laboratory (lab of the woman's health university hospital). research design: prospective study (randomized controlled trial) . setting: this study will be conducted at the outpatient clinic of the woman's health university hospital, assiut university. sample size: convenience sample started from february 2020 to january 2023 or reached 120 cases, 60 in each arm. statistical analysis data entry and statistical analysis will be done using the statistical package for social science program (spss. version 22). qualitative variables will be presented as number and percentage. quantitative variables will be presented as mean +sd. comparison between qualitative variables will be done by using chi-square. comparison between quantitative variables will be done by using student t-test.

Eligibility criteria:
inclusion criteria: 1. pathologic hyperprolactinemia due to any cause. 2. non-pregnant. 3. not lactating. exclusion criteria: 1. physiologic hyperprolactinemia. 2. women who don't consent for follow up.

Keywords: health education prolactin hyperprolactinemia resistant
cerebral oximetry and neurocognitive functions in cardiosurgical patients

Conditions: Coronary Artery Disease; Postoperative Cognitive Dysfunction; Neurological Impairment

Summary: it is previously reported that the cerebral oxygen desaturation during cardiac surgery is associated with an increased incidence of cognitive impairment. the aim of this study is to determine whether intraoperative monitoring and predetermined interventions protocol to improve cerebral oxygenation during coronary artery bypass surgery provides benefits in neurocognitive functions.

neurologic complications are major cause of morbidity following coronary artery bypass graft surgery. the neurologic injuries range in severity from subclinical cognitive changes to fatal brain injury and death. these complications represent a big impact on overall morbidity, and mortality in association with increased costs and length of hospital stay. the social impact is also very important with consequences on patients' quality of life. several studies reported the incidence of cognitive decline after cardiac surgery that ranges from 30 to 80%. the most common etiologies are embolization and hypoperfusion of the brain. the in vivo optical spectroscopy (invos) system uses near-infrared spectroscopy (nirs) and provides noninvasive and continuous information on changes in regional oxygen saturation of blood in the brain (rso2). when rso2 decline occurs it can be responded with simple interventions to prevent a brain injury. these interventions include: repositioning of the head or perfusion cannulae, increasing arterial carbon dioxide tension, increasing oxygen inspiration concentration, increasing arterial blood pressure, adjusting pump flow rate, temperature decreasing, increasing of anesthetic depth and blood transfusion. recent studies reported that intraoperative cerebral oxygen desaturation is associated with early postoperative neuropsychological dysfunction in patients undergoing cardiac surgery. neurocognitive function can be assessed with battery of standardized neurocognitive tests. mini mental state examination, color trail test, grooved pegboard test are easy to perform bedside tests that test orientation, registration, attention, calculation, recall, language and complex visual-motor coordination.

Eligibility criteria:
inclusion criteria: * all patients with coronary artery disease undergoing coronary artery bypass grafting (cabg) with cardiopulmonary bypass exclusion criteria: * who refuse to participate * previous stroke * preexisting psychiatric disease * significant carotid stenosis * ejection fraction below 25% * reoperations * emergent surgery * dialysis

Keywords: cerebral oximetry nirs invos